Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$20.54 +2.0%	$20.50	$17.24 ▼ $30.41	$13.59B	1.07	1.05 million shs	769,590 shs
ITCI Intra-Cellular Therapies	$131.87	$131.08	$64.09 ▼ $131.98	$14.05B	0.69	1.46 million shs	N/A
PTCT PTC Therapeutics	$49.55 -0.8%	$50.07	$24.00 ▼ $58.38	$3.91B	0.58	812,443 shs	806,716 shs
TEVA Teva Pharmaceutical Industries	$14.71 +2.9%	$15.26	$12.47 ▼ $22.80	$16.68B	0.72	9.94 million shs	8.36 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	-0.67%	+2.99%	+4.38%	-5.43%	-29.50%
ITCI Intra-Cellular Therapies	0.00%	0.00%	+0.13%	+3.78%	+78.18%
PTCT PTC Therapeutics	+3.65%	+7.63%	-12.41%	+8.16%	+96.58%
TEVA Teva Pharmaceutical Industries	+2.07%	+6.56%	-11.61%	-34.24%	+9.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	4.2238 of 5 stars	4.3	5.0	0.0	0.0	2.5	0.0	3.1
ITCI Intra-Cellular Therapies	2.2212 of 5 stars	1.1	3.0	0.0	4.5	1.1	1.7	0.6
PTCT PTC Therapeutics	3.8685 of 5 stars	4.3	1.0	0.0	4.4	3.2	0.8	0.0
TEVA Teva Pharmaceutical Industries	3.0849 of 5 stars	3.4	5.0	0.8	0.0	3.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	90.68% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
PTCT PTC Therapeutics	2.53	Moderate Buy	$63.92	29.01% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	59.27% Upside

Current Analyst Ratings Breakdown

Latest PTCT, TEVA, ITCI, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	PTCT PTC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$65.00 ➝ $65.00
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/31/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$78.00 ➝ $75.00
3/14/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$72.00 ➝ $78.00
3/11/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
3/11/2025	GMAB Genmab A/S	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/11/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$41.00 ➝ $55.00
3/7/2025	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$67.00 ➝ $70.00
3/7/2025	PTCT PTC Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$55.00

(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$21.53B	0.63	$1.39 per share	14.80	$8.04 per share	2.55
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
PTCT PTC Therapeutics	$806.78M	4.84	$2.38 per share	20.80	($10.85) per share	-4.57
TEVA Teva Pharmaceutical Industries	$16.54B	1.01	$2.91 per share	5.05	$4.75 per share	3.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.74	11.80	11.54	2.65	36.30%	16.78%	13.79%	5/8/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	5/6/2025 (Estimated)
PTCT PTC Therapeutics	-$626.60M	-$4.73	N/A	N/A	N/A	-50.32%	N/A	-16.44%	4/24/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.59	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest PTCT, TEVA, ITCI, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.26	N/A	N/A	N/A	$5.17 billion	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	N/A	N/A	N/A	$3.99 billion	N/A
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	N/A	N/A	N/A	$437.16 million	N/A
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.87%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.25	5.24
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
PTCT PTC Therapeutics	N/A	2.10	2.04
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
PTCT PTC Therapeutics	N/A
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
PTCT PTC Therapeutics	5.50%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	1,660	661.77 million	651.58 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
PTCT PTC Therapeutics	1,410	78.87 million	72.88 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

PTCT, TEVA, ITCI, and GMAB Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by BlackBarn Capital Partners LP

April 24 at 7:29 AM | marketbeat.com

300,000 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Diadema Partners LP

April 24 at 7:16 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Slate Path Capital LP's 9th Largest Position

April 24 at 7:10 AM | marketbeat.com

Eversept Partners LP Sells 992,513 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 24 at 7:08 AM | marketbeat.com

Continental Advisors LLC Sells 20,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 24 at 6:50 AM | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Invests $6.01 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 23 at 5:34 AM | marketbeat.com

CANADA LIFE ASSURANCE Co Raises Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 23 at 4:51 AM | marketbeat.com

Teachers Retirement System of The State of Kentucky Invests $37.69 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 22 at 7:07 AM | marketbeat.com

Capital International Investors Has $58.73 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 22 at 5:01 AM | marketbeat.com

Beck Mack & Oliver LLC Sells 36,160 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 21 at 7:41 AM | marketbeat.com

JB Chemicals & Pharma receives USFDA approval for Bisoprolol Tablets

April 21 at 5:37 AM | business-standard.com

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

April 21 at 3:51 AM | fool.com

Gamco Investors INC. ET AL Reduces Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 20, 2025 | marketbeat.com

39,413 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by CreativeOne Wealth LLC

April 20, 2025 | marketbeat.com

Altshuler Shaham Ltd Has $4.36 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19, 2025 | marketbeat.com

Marshall Wace LLP Purchases 2,410,420 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19, 2025 | marketbeat.com

Gabelli Funds LLC Acquires 183,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19, 2025 | marketbeat.com

Raymond James Financial Inc. Buys Shares of 1,765,593 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 18, 2025 | marketbeat.com

Russell Investments Group Ltd. Has $4.51 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 18, 2025 | marketbeat.com

Affinity Asset Advisors LLC Sells 1,000,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 17, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Holdings Increased by Jump Financial LLC

April 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, TEVA, ITCI, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$20.54 +0.41 (+2.04%)

As of 04:00 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

PTC Therapeutics NASDAQ:PTCT

$49.55 -0.40 (-0.80%)

As of 04:00 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Teva Pharmaceutical Industries NYSE:TEVA

$14.71 +0.42 (+2.94%)

As of 03:59 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time